Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05525507 · ClinicalTrials.gov registry record · Phase 1

Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants

A Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT05525507: Recruiting Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, sponsored by University of California, Los Angeles.

NCT05525507 is a Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 10 participants, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05525507, a Phase 1 study of Chronic Kidney Diseases and End-Stage Kidney Disease, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).

Primary Outcome

To determine whether patients with pre-existing kidney transplants from a haploidentical living donor can be withdrawn from immunosuppressive drugs while maintaining stable graft function within 12 months of hematopoietic stem cell infusion from the same HLA-identical living donor, preceded by conditioning with TLI and ATG.

Interventions

  • COMBINATION_PRODUCT Conditioning and Stem cell infusion

Study Locations (1)

California

  • UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-12-21
Est. Completion 2026-12
Phase Phase 1

What NCT05525507 shows while recruiting

NCT05525507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which Conditioning and Stem cell infusion is the first listed.

NCT05525507 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05525507 about?

NCT05525507 is a clinical study titled "Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants". The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC inf...

What is the current status of trial NCT05525507?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-12-21. Estimated completion is 2026-12.

What conditions does trial NCT05525507 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases, End-Stage Kidney Disease, Kidney Transplant Failure and Rejection, Immunological Tolerance.

What interventions are being tested in trial NCT05525507?

The interventions under investigation include: Conditioning and Stem cell infusion (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05525507?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05525507 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05525507's enrollment target sits among peer trials

10 73rd of 73 higher than 1 of 73 other Chronic Kidney Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05525507, the US trial registry maintained by the National Library of Medicine. NCT05525507 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.